Managing Technological Uncertainty in Science Incubation:A Prospective Sense-Making Perspective by Friesl, Martin et al.
Published 2019 in  R&D Management 49 (4), 668-683 
1 
 




Martin Friesl* / Chris J. Ford / Katy Mason 





This paper focuses on the adaption challenge that confronts the top management team (TMT) 
of science incubators in situations of substantial technological uncertainty. To do that, we draw 
on the three-year longitudinal analysis of a major bioscience catalyst in the UK. Through the 
lens of ‘prospective sensemaking’, we follow the TMT as they work with stakeholders in their 
ecosystem to make sense of a significant technological shift: the convergence of life sciences, 
IT and other sciences in the health care environment. Our analysis reveals how prospective 
sensemaking resulted in the launch of a new strategy to exploit these emerging opportunities. 
However, stakeholders’ increasingly fragmented interpretation of the term convergence and 
the anticipation of legitimacy challenges in the wider ecosystem resulted in the repositioning 
of the incubator. Our findings contribute to extant research on science incubation. In particular, 
the paper sheds light on the complex interactions of incubator TMT’s with stakeholders in 
situations of technological change and uncertainty. Moreover, responding to technological 
change does not only affect the structural conditions of an incubator. Rather, it may also require 
changes to the positioning of the incubator in order to maintain legitimacy in the wider 
ecosystem. The paper also suggests managerial as well as policy level implications.   
 








Science parks and incubators have become a growing area of research due to their implications 
for innovation and regional development (Ford et al., 2010; Siegel et al., 2003; Soetanto & 
Jack, 2016). Incubators are organizations, often backed by public and / or private funding, that 
can be defined as “property-based initiatives providing tenant firms with a portfolio of new 
venture support infrastructure […]” (Mian et al., 2016, 2). Such infrastructure may involve 
office space, skill development and access to networks and funding in order to nurture firm 
growth (Bruneel et al., 2012). While incubators are set up based on a specified mandate, often 
in a particular technological domain (e.g. pharmaceuticals, digital technologies etc.), 
incubators are also evolving, as managers respond to changing technological demands in their 
ecosystem (Koh et al., 2005; Phan et al., 2005). An incubator’s ecosystem is comprised of its 
external relationships (Iyer et al., 2006), such as entrepreneurs, universities or venture 
capitalists. Yet, how the management of incubators responds to technological change, while 
addressing the demands of these multiple, interconnected organisations has received limited 
attention in extant research. Indeed, prior research has either taken an institutionalist 
perspective by tracing the evolution of incubation ‘models’ (Mian et al., 2016) or has remained 
conceptual without explaining the mechanisms through which science incubators adapt to 
technological change (Koh et al., 2005).  
Incubators can only facilitate innovation if they are closely attuned to the needs of the 
entrepreneurial firms within them (McAdam & McAdam, 2008; Peters et al., 2004; van Weele 
et al., 2017). Significant technological changes potentially require incubators to adapt their 
incubation model in order to remain relevant and effective (Hsu et al., 2003). Thus, the 
challenge for the management teams of incubators is to anticipate changes in technology that 
would substantially affect their raison d’etre, the portfolio of tenants, as well as the activities 
and networks deployed in the process of incubation (Koh et al., 2005; Phan et al., 2005). Yet, 
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how incubators respond to technological change and the process through which incubator 
managers make decisions about such changes, has only received limited research attention 
(Bruneel et al., 2012). 
We follow research on strategy practice and process (Balogun & Johnson, 2004; Gioia & 
Chittipeddi, 1991; Stensaker et al., 2008) and argue that understanding the evolution of science 
incubators requires us to investigate how the top management of incubators create meaning 
from uncertain technological change. An important theme in strategy practice and process 
research is how managers prospectively make sense of poorly understood events that are still 
unfolding (Stigliani & Ravasi, 2012; Weick et al., 2005). Such prospective sensemaking often 
occurs in collaboration with external stakeholders (Werle & Seidl, 2015). Based on this 
perspective we address the following research question: How does the collective prospective 
sensemaking of incubator managers and external stakeholders influence the adaptation of a 
science incubator to a new technological trend?  
We draw on the longitudinal case analysis of Stevenage Bioscience Catalyst (SBC), an 
incubator jointly funded by GlaxoSmithKline, The Welcome Trust and the UK government. 
We analyse how SBC’s top management team (TMT) engages with substantial technological 
uncertainty caused by what they termed ‘Convergence’: the coming together of multiple 
technologies and sciences including biotechnology, chemistry, information technology and 
mechanical engineering, as they collectively relate to the development and production of new 
drugs. Our paper follows SBC’s TMT as they work ‘with’ stakeholders in their ecosystem over 
the 2013 to 2016 period, as they attempt to ensure that the incubator works ‘for’ the ecosystem 
in an environment of converging technologies. 
Changes in SBC’s ecosystem triggered prospective sensemaking regarding the meaning 
and implications of Convergence for the incubator. The term Convergence and the underlying 
health care opportunities were adopted as key pillars of SBC’s strategy that was supposed to 
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ensure SBC’s legitimacy as a leading incubator in the wider ecosystem. Yet, prospective 
sensemaking also resulted in two critical sensemaking outcomes: First, prospective 
sensemaking, in collaboration with a broad group of stakeholders, highlighted that 
Convergence had significantly different meanings for different stakeholder groups. Second, 
based on this fragmentation of meaning, the TMT anticipated legitimacy challenges within its 
ecosystem if the notion of Convergence was retained in its strategy. SBC responded by 
repositioning the incubator around the notion of ‘Future Health’, yet continued to align the 
incubator structurally, with the wider trend of Convergence. Our findings contribute to the 
growing debate on science incubation by providing insights into the inner workings of how 
incubators adapt to technological change and uncertainty.  
2. Evolution of science incubators 
2.1. Strategic change of science incubators: State of research 
Science incubators form the empirical context for a growing body of research on innovation 
and entrepreneurship (Albort-Morant & Ribeiro-Soriano, 2016; Clarysse et al., 2005; Mian et 
al., 2016; Phan et al., 2005; Thierstein & Wilhelm, 2001). Extant research has investigated the 
influence of incubators on the regional, national and international economy (e.g. Albort-Morant 
& Ribeiro-Soriano, 2016; Hsu et al., 2003) and has also studied the incubation process. This 
includes the activities of incubation embedded in the tenant-incubator relationship (e.g. 
Ahmad, 2014; Becker & Gassmann, 2006; Markovitch et al., 2017; Mian, 1996; Soetanto & 
Jack, 2016) and the implications of networks for tenant companies’ performance (Bøllingtoft 
& Ulhøi, 2005; Collinson & Gregson, 2003; Díez-Vial & Montoro-Sánchez, 2016; Ebbers, 
2014; Sá & Lee, 2012). An emerging strand of research relates to the processes and 
mechanisms through which such organizations change over time. We differentiate between two 
distinct perspectives: institution level studies of incubation models and micro-level analyses of 
the dynamics of incubator change.  
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By taking an institutionalist view, Mian et al. (2016) trace how science incubation as a 
particular form of economic activity has changed since the ‘first-wave’ before the 1980s, 
compared to the complex and multi-faceted incubation models of today. This suggests that 
incubation models are contingent on particular technological and economic contexts, which are 
dynamic and subject to change (Phan et al., 2005; Shepard, 2017). Indeed, Koh et al. (2005) 
point out that “if a science park or technology district is unable to renew itself through new 
sources of growth, decline will set in” (p. 225). They argue that it is crucial for incubators to 
be able to embrace new, emerging technologies and incorporate these into their incubation 
practice. Similarly, Phan and colleagues (2005) raise the question of whether science 
incubators can actually develop dynamic capabilities (Eisenhardt & Martin, 2000; Teece et al., 
1997): processes or routines that would allow them to transform their incubation approach as 
times change, whilst retaining their legitimacy in relation to key stakeholders. 
Yet, despite calls for empirically investigating the dynamic nature of incubators (Koh et 
al., 2005; Phan et al., 2005), the micro-level mechanisms through which incubators deal with 
changes in technology have only received limited research attention. One of the most 
substantial empirical studies is Bruneel et al.’s (2012) comparative study of incubators, which 
proposes a model of ideal-typical incubation approaches and their evolution. This study does 
not trace the underlying dynamics within an incubator but does point out how different 
incubation models evolved with regard to infrastructure, business support and access to 
networks. Hsu and colleagues (2003) show how the evolution of a science incubator in Taiwan 
is linked to the development of a wider technology cluster in which it was embedded. 
Rather than tracing the evolution of incubators at the institutional level, we follow calls in 
prior research and investigate how such evolution may actually occur through activities at the 
micro-level (Bruneel et al., 2012; Koh et al., 2005; Phan et al., 2005). Research on strategy and 
organization highlights how the evolution of firms is influenced by how management teams 
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interpret events. These interpretations may give rise to strategic transformation (Dutton, 1993; 
Laamanen & Wallin, 2009) or may also underpin inertia and difficulties for change (Staw et 
al., 1981; Tripsas & Gavetti, 2000). Thus, an important avenue to understanding the evolution 
of science incubators is to investigate managers’ interpretations of the future implications of 
technological change. 
2.2. Theoretical perspective 
A core tenet of strategy practice and process research is to explore macro-level phenomena 
(such as the evolution of science incubators), by investigating the micro-level activities that 
give rise to these phenomena (Johnson et al., 2007; Johnson et al., 2003; Whittington, 2006). 
Strategy practice and process research often explains organizational change by investigating 
how managers make sense of events (Balogun & Johnson, 2004; Gioia & Chittipeddi, 1991; 
Stensaker et al., 2008). The notion of sensemaking describes the complex, inter-personal 
process through which actors create or change meaning in an uncertain world (Balogun & 
Johnson, 2004; Weick, 1995). Sensemaking is usually considered a retrospective process, 
triggered by, for instance, crises and break-downs of practice that render existing meaning 
systems obsolete (Maitlis, 2005). A classic example of such a study is Weick’s reinterpretation 
of the Mann Gulch fire disaster (Weick, 1993).  
However, recent research argues that sensemaking does not only happen retrospectively, 
but may also occur prospectively; as actors aim to understand events as they unfold in order to 
develop a suitable response (Güttel et al., fc; Jacobs et al., 2013; Sandberg & Aarikka-Stenroos, 
2014; Stigliani & Ravasi, 2012). Prospective sensemaking involves the sharing of ‘provisional’ 
and ‘tentative’ understandings amongst actors, often with external stakeholders (Werle & Seidl, 
2015). This may require multiple interactions over time, through which these understandings 
are refined (Stigliani & Ravasi, 2012; Weick et al., 2005). As prospective sensemaking 
involves actors’ engagement with yet uncharted and unfamiliar trends, it “provides the 
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opportunity for the prolonged and conscious articulation and elaboration of tentative 
interpretations.” (Stigliani & Ravasi, 2012, 1250) Managers rely on these interpretations when 
making decisions about the future of organizations (Gephart et al., 2010).  
Prospective sensemaking is of particular importance in innovation and high technology 
contexts, where information about new technologies and their evolutionary paths is, by 
definition, incomplete. Technologies are often only vaguely defined, and their meanings for 
particular user groups are not obvious (Daft et al., 1987; Schneckenberg et al., 2017). The 
uptake of technologies (as portrayed in the media) is always subject to political agendas and 
may thus be hyperbolic (Rosenberg, 1994; Swanson & Ramiller, 1997). As Berente et al. (2011, 
686) argue “individuals construct the future of equivocal technologies rather than simply apply 
them (Daft et al. 1987; Weick 1990).” For instance, Jacobs and colleagues (2013) draw on 
prospective sensemaking to study how designers envisage potential uses of a technology. 
Moreover, the involvement of external stakeholders as part of prospective sensemaking is 
highly likely in the case of science incubators due to their strong network and ecosystem 
embeddedness (Phan et al., 2005). 
Thus, in this paper we focus on the collaborative, prospective sensemaking of incubator 
managers and external stakeholders in the context of significant technological change and 
uncertainty and thus aim to answer the following research question: How does the collective 
prospective sensemaking of incubator managers and external stakeholders influence the 
adaptation of a science incubator to a new technological trend?  
3. Methodology 
We draw on the longitudinal, inductive analysis of a single case (Easterby-Smith et al., 2008; 
Langley et al., 2013; Yin, 2009). The single case design allows us to follow the sensemaking 
of actors at SBC over time (Maitlis, 2005). Below we describe the research context as well as 
our approach to data collection and data analysis.  
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3.1 Research context 
Addressing our research question required a context characterized by substantial technological 
changes; changes that are still unfolding with unclear consequences for incubators. This paper 
is based on the three-year study of Stevenage Bioscience Catalyst (SBC). GlaxoSmithKline 
(GSK), The Welcome Trust, and the UK government set up SBC in 2011 as a not-for-profit 
incubator, by. SBC’s main strategic priority is to use principles of open innovation to nurture 
next generation bioscience companies. Thus, the TMT focused on maximizing collaboration in 
as many areas of the organization as possible. By 2013, a trend called ‘Convergence’ has 
become increasingly salient: the coming together of sciences such as information technology 
and mechanical engineering in the bioscience innovation sphere. Technology convergence has 
since also been the object of innovation research (e.g. Maine et al., 2014).  
While Convergence was already discussed at major conferences, the TMT was unsure how 
it would affect SBC. We trace the TMT’s engagement with the phenomenon of Convergence 
over time. While Convergence was quickly adopted as a new ‘agenda’ for SBC in 2013, the 
term was ultimately abandoned in 2016. Thus, SBC is a revelatory case as it provides insights 
into prospective sense making and its implications for organisational change at a science 
incubator faced with technological uncertainty (Yin, 2009). Table 1 provides an overview of 
the development of SBC between 2013 and 2016. 
---------------------------------------------- 
INSERT TABLE 1 HERE 
---------------------------------------------- 
3.2 Data sources 
This paper forms part of a larger, longitudinal study of bioscience incubation at SBC (Mason 
et al., fc, 2017). For the purpose of this paper, we only used those parts of the data set that 
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provide insights into prospective sensemaking regarding technology convergence and the 
background of SBC. We draw on the following data sources for our analysis: 
---------------------------------------------- 
INSERT TABLE 2 HERE 
---------------------------------------------- 
We draw on 34 semi-structured interviews (26 interviews with SBC management and 8 
interviews with tenant firms) in order to understand the bioscience industry, the incubation 
process at SBC, and the TMT’s interpretation of technology convergence. Interviews lasted 
between 30 minutes and 2 hours and were recorded and transcribed verbatim. In addition, we 
also collected data from two ‘Convergence Workshops’ and a conference on the theme of 
‘Future Health’, all organized by SBC. These events were attended by the top management 
team as well as industry experts. The 2015 workshop was recorded and transcribed verbatim, 
and we were also provided with the workshop minutes. The 2013 workshop was recorded in 
contemporaneous hand written notes by the attending researchers, and we were provided with 
a whitepaper written as a summary by SBC staff after the event. These data sources provide in-
depth insights into the prospective sensemaking of the TMT and other stakeholders. Finally, 
we also collected further documentation. This involves seven SBC strategy and planning 
documents outlining the objectives of the incubator as well as nine industry reports on 
technology convergence in the biosciences.  
3.3 Data analysis 
Drawing on a process approach, we reconstructed the TMT’s collective prospective 
sensemaking with actors in their ecosystem, regarding the meaning and the implications of 
technology convergence (Langley, 1999; Langley & Tsoukas, 2010). We used NVivo to 
organize and analyse the data. In a first stage of analysis, we created a timeline of key events 
regarding SBC management team’s engagement with technology convergence (for a summary 
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see Table 2). We used the two Convergence Workshops in 2013 and 2015 as well as interviews 
with SBC management in order to create three distinct phases. Phase 1 (2013-2014), is 
characterized by the initial sensemaking around the meaning of Convergence. Phase 2 (2015), 
in turn, sees a shift towards a more critical stance towards the implications of technology 
convergence. Finally, in phase 3 the notion of Convergence is abandoned.  
In a second stage of analysis, we compiled a data set for each of the three phases and wrote 
up first order descriptions emphasizing key events. In a third stage of analysis, we focussed on 
the prospective sensemaking that took place in each of those phases. To do that, we looked at 
accounts in interviews, documents or workshop recordings that mentioned Convergence and 
in which actors discussed the term. Similar to prior studies on sensemaking (Gioia & 
Chittipeddi, 1991; Stigliani & Ravasi, 2012), we assigned descriptive themes that broadly 
described the objective of sensemaking, for instance ‘bridging and blurring of disciplinary 
boundaries’, ‘Struggle to explain convergence to stakeholders’ or ‘change in composition of 
tenant portfolio’ (see Figure 1).  
In a fourth stage of analysis, we compared these themes in several iterations in order to 
develop aggregate, conceptual themes. Figure 1 provides the final data structure with first-
order categories, second-order themes and aggregate dimensions and Table 3 includes 
supporting evidence for each of the conceptual themes. Moreover, the temporal sequencing of 
themes across phases 1-3 allowed us to theorize the dynamics of prospective sensemaking 
shown in Figure 2.   
---------------------------------------------- 
INSERT FIGURE 1 HERE 
---------------------------------------------- 




INSERT TABLE 3 HERE 
---------------------------------------------- 
4. Making sense of technology convergence at SBC 
Below we describe how SBC engaged in prospective sensemaking in order to engage with the 
trend of technological convergence that has the potential to revolutionize the provision of 
healthcare.  
4.1 Phase 1: Convergence - making sense of an emerging trend (2013-2014) 
Sensemaking triggers. In 2013, SBC’s TMT was aware of an increasing discussion in the 
bioscience arena with regard to the potential future convergence of various technologies. 
Indeed, the notion of Convergence had been discussed for a few years and it had already formed 
the focus of an MIT report in 2011. This report calls Convergence the ‘Third Revolution’ and 
a radical shift in how research is conducted as different knowledge domains such as 
microbiology, computer sciences and engineering are combined (MIT, 2011). Leading 
scientific advisors to the National Science Foundation (NSF) also published a book in 2013 
pointing out the implications of this phenomenon (Roco et al., 2013). Yet, in 2013 SBC was 
neither clear about the meaning of the term, nor the actual implications for them as a science 
incubator. Despite this ambiguity, however, it was perceived to be a significant enough 
opportunity for them to focus their annual Open Innovation Summit on this theme, giving it 
the title “Convergent Medical Technologies”. During this period, Convergence also raised 
questions in the professional media with commentators pointing out that an increasing number 
of start-ups “stretched over more than one category. They incorporated elements of a device 
and digital health or diagnostics.” (Combs, 2014).  
Sensemaking around strategic implications of technology convergence. As a response to 
these early signals, and the apparent success of their 2013 event, the TMT invited a number of 
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industry experts to a workshop in order to discuss convergence as a future trend of potentially 
high significance for SBC. Workshop participants included experts from the NHS, research 
organizations, entrepreneurs as well as major pharmaceutical corporations. They agreed that 
Convergence is a wider phenomenon and discussed that firms in a number of industries were 
working on Convergence. There was also an initial assumption that different technology 
domains coming together had the potential to deliver against a number of important patient 
needs such as certain types of “vaccines, diseases of the brain and early cancer detection.” 
(SBC White Paper July 2013). SBC framed this as an opportunity to continue acting as a 
“catalyst for innovation” (SBC Workshop Minutes, June 2013).  
Yet, the TMT as well as external participants also discussed potential challenges involved 
in realizing a ‘Convergence Agenda’ as it came to be called. The big challenges were envisaged 
to be cultural and financial in nature. An important implication of the convergence of different 
scientific disciplines is the increased need for coordination across disciplinary boundaries. 
Bridging these cultural boundaries was considered a major challenge: there are “different 
language in different disciplines – are we talking in digital code or patents? [there is a] lack 
of understanding at the upper echelons of companies” (SBC Whitepaper, July 2013). At the 
same time, workshop participants also predicted a funding gap as convergent technologies 
would, by definition, fall in between any established ways of classifying and evaluating 
technologies. Thus, attracting venture capital funding could potentially be difficult due to a 
legitimacy void: “People don’t invest in early stages until you have something that everyone 
would invest in” (SBC White Paper, July 2013). 
Outcome of phase 1: The vagueness of the term Convergence created issues for SBC’s 
management team. It raised questions regarding appropriate responses that would enable SBC 
to embrace this trend and leverage it for its growth plans. As the discussions around the 
meaning and implications of Convergence had only just started, the CEO concluded that it was 
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too early for implementing any changes to the incubation model. He argued that the only thing 
SBC could really do in order to prepare was to be ‘ready’; to embrace the change and remain 
alert by being “unafraid of the unknown, comfortable with ambiguity.” (SBC White Paper, 
July 2013) 
4.2 Phase 2: Fragmentation of meaning and anticipated legitimacy challenge (2015) 
By 2015, the notion of convergence had gained substantial traction in the wider bioscience 
community with major conferences and industry reports devoted to this topic. SBC was keen 
to be at the forefront, and SBC staff routinely talked about the ‘Convergence Agenda’ as the 
future of the organization. In 2015, SBC also accepted a new tenant firm that tried to leverage 
the opportunity of delivering towards unmet patient needs by incorporating expertise in the 
manufacturing of semi-conductors into cell-therapy applications, a prime example of 
technology convergence. In a continued attempt to  understand what Convergence meant and 
how SBC would have to change, SBC organized a second workshop attended by a number 
industry experts ranging from Pharma, Venture Capital, IT and Consulting in October 2015. 
The brief of the workshop was very simple: what is convergence and what do we need to do?  
Fragmentation of meaning: Until this point SBC’s sensemaking of Convergence mainly 
involved the coming together of IT, engineering and biosciences. Yet, throughout the 
workshop, this understanding was substantially challenged. The following examples show 
how, in the course of the workshop, the meanings started to fragment, as multiple 
interpretations reflected widely varying perspectives, agendas and expectations about what 
may, or may not, be converging. In an attempt to frame the discussion, one of the workshop 
participants started to map out a typology of convergence: 
“there’s sort of almost two types of convergence and they might themselves be converging initially [….] 
One type of convergence is the data aspect and I think in terms of the patient journey [and] public health 
[…] the second convergent strand […] was around microelectronics.” (October 2015) 
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Thus, not only are there different types of convergence, these types are again assumed to 
converge thus creating an even more complex picture. Moreover, other experts, such as a 
technology consultant, started to even further expand what the term convergence actually 
meant:  
“Can I also just push the meaning of convergence a bit further? Wearables are one thing, it’s a bit of tech 
sitting next to a patient but I think what really gets SBC excited is the technology that becomes part of the 
patient.” (October 2015) 
Also, while IT was still considered to be one of the key convergent sciences by SBC this was 
increasingly questioned by participants: 
“I agree that health IT is kind of all-pervasive but there are bits of convergence that I think are at the other end 
of the spectrum like regenerative medicine. Which is where there are lots of other strands that are converging 
like how you deliver it to the patient, how do you monitor it in the patient all these kinds of things. Obviously 
IT is going to be a component of it but it’s not the most important component” (October 2015) 
The result was an increasing fragmentation of meaning amongst stakeholders. We use the term 
fragmentation to describe the variance in interpretation across multiple stakeholders. 
Anticipated legitimacy challenge: The fragmentation of meaning alerted the TMT to the 
danger of building its espoused strategy on such a fuzzy concept. Up to this point, the 
challenges of making Convergence happen were particularly seen on the level of collaboration 
and the acquisition of funding. In this workshop, the discussion shifted to SBC’s legitimacy as 
a major UK science catalyst. Indeed, SBC had to make sure, that the ability to make 
Convergence happen could be credibly demonstrated to key stakeholders (such as government 
funding bodies and big pharma). This concern is expressed in the following quote in which 
SBC’s Business Development Manager admitted that she refrained from using the phrase due 
to the lack of traction in the medical community: “I haven’t really badged things as convergent 
medical technologies, because it doesn’t mean anything to the academic community” (October 
2015). In addition, workshop participants started to doubt whether the medical field as a whole 
would be receptive to such a complex development: “Do the doctors really want this stuff to 
be shifted out of their laps?” These anticipated challenges to the legitimacy of the notion of 
Convergence resulted in changes in how SBC’s management continued to engage with this 
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phenomenon: Whilst the underlying trend of converging technologies was not in question, what 
became problematic was how SBC, as a science catalyst, should embrace it.  
Organizational sensemaking outcome – Positioning and structural changes: The 
organizational implications of Convergence were now considered more serious for SBC than 
previously assumed. During the discussion it emerged that the existing ways of operating 
would probably not be sufficient in a scenario of converging sciences. Already before the 
workshop, the CEO envisaged a shift in the ‘business model’ of SBC as a science catalyst:  
“we don’t want to reinvent the wheel. If it’s good and it works we won’t break it but we think open 
innovation and certainly convergence, and I’ll come onto to explain why, requires new business models.” 
(May 2015) 
Rather than pure science incubation, involving the close work with fledgling businesses, 
technology convergence would require incubators to become mediators in a complex cross-
industry value chain: 
 “SBC could bring real value and attract companies in the space if we could find a way of orchestrating 
and catalysing activities, more than just brokering introductions but actively supporting the entrepreneurs 
and helping them to build their businesses.” (Workshop Minutes, July 2015) 
In order to fulfil this role, SBC would also have to alter the composition and diversity of its 
tenants, in order to reflect the various converging sciences. For example, in March 2015, SBC 
included two projects focused on manufacturing processes spear headed by UCL (University 
College London). Another initiative was the inclusion of the ‘Cell Therapy Catapult’ in 2015, 
an initiative to translate research into new forms of therapies. Linking SBC to the Cell Theory 
Catapult was “one of [the] focus areas in the convergence space”, as the CEO pointed out. In 
addition to these ‘structural’ adaptations, the TMT increasingly used the phrase ‘convergence 
agenda’ in slide decks that communicated the position of SBC in the wider ecosystem of firms 
as well as its objectives for the future.  
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4.3 Phase 3 – Repositioning: From convergence to ‘Future Health’ (2016) 
By 2016, technology convergence was well established as a theme and substantial research 
budgets were made available. For instance, the NSF declared Convergence as one the top 10 
themes for future investments (NSF, 2016). Moreover, professional service firms used the 
Convergence theme in their communications. Accenture, a major consultancy, published a blog 
post claiming an “inflection point with healthcare and emerging technologies converging” 
(Ural, 2016). Convergence was considered to be of major importance for future of health care. 
For instance, leading scientists at Massachusetts Institute of Technology (MIT) compiled a 
major report, which aimed to define what Convergence meant and map out the opportunities 
for health care. This report defined Convergence as: “the integration of historically distinct 
disciplines and technologies into a unified whole that creates fundamentally new opportunities 
for life science and medical practice.” Yet, it also acknowledged the inherent practical 
challenges of bringing these domains together (Convergence – The future of health report, 
2016, 17) In the same year, the NSF put a similar definition forward. It also reiterated the 
potential for solving some of the most challenging problems.  
Anticipated legitimacy challenge: In line with these developments at industry level, the 
TMT’s sensemaking was no longer restricted to the meaning or opportunities of Convergence. 
By 2016, these were taken as a given. In contrast, an important outcome of prospective 
sensemaking and the increasing fragmentation of meaning regarding the term Convergence 
triggered growing concerns of legitimacy and the risk involved in shifting away from SBC’s 
current business model (which was proving to be successful), to a yet unproven idea. 
“Our stakeholders are so complimentary about how we have delivered an open innovation campus 
focussing on biotech, [with a] portfolio of 50 [organizations], with a mix of business and academia, 
corporates and small firms. And now you say, we are gonna expand the business model. And all of a sudden 
you are adding on something and you have to convince them that this is a natural extension [of SBC]” 
(CEO, February 2016)  
Still, engaging with Convergence as a trend was inevitable and there remained no doubt that 
this would be an important element in the future of healthcare.  
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Organizational sensemaking outcome - Repositioning: The CEO and the COO realized 
that they had to divorce the underlying industry level trend of different technologies and 
sciences coming together from the label Convergence. While the former proved to be crucial 
the latter became problematic. They realized that in order to create legitimacy amongst 
healthcare professionals in the UK they would have to reposition themselves. This legitimacy 
was key to ensuring that SBC could continue with its successful incubation model and tenant 
groups, while progressively building capabilities in the convergent technologies space. As a 
result, despite the wide spread use of the term in science media, SBC decided to move away 
from the phrase Convergence as expressed in the following quote of SBC’s COO in June 2016: 
“We move away from this term convergence. Because it’s…it’s confusing people. We now 
actually talk about Future Health.” This new phrase was launched at SBC’s annual Open 
Innovation Summit 2016, which brought together industry experts, academics and major 
stakeholders. While SBC continued to consider technology convergence in managing and 
expanding its tenant portfolio (in particular by engaging with the Cell Therapy Catapult), the 
notion of ‘Future Health’ allowed them to engage with their key stakeholders in a more 
constructive way. In particular, they avoided the need to alter their now-well-established 
business model, and continue to seek potential tenants that contributed to the Future of Health 
through more widely recognised and established channels.  
5. Discussion 
Our analysis traces the process and outcomes of prospective sensemaking of the management 
team of an incubator faced with substantial technological uncertainty. Below we provide a 
conceptual interpretation of the longitudinal case analysis and discuss theoretical contributions 
of our findings.  
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5.1 Prospective sensemaking and technological change in science incubation: a process model 
The recent advances in strategy process and practice research  highlight the need to study 
individual or group level dynamics in order understand organization level change (Vaara & 
Whittington, 2012). Following SBC’s TMT as they aimed to understand an emerging 
technological transformation provides deep insights into the dynamics underpinning the 
evolution of science incubators faced with technological change. By bringing together both 
internal and external stakeholders (such as scientists, venture capitalists and consultants), SBC 
engaged in collective, prospective sensemaking. This was an attempt to create a shared 
understanding of the characteristics of technological transformation (‘what does Convergence 
mean’) and the opportunities and threats involved but also how this technological shift would 
affect the very process of incubation. Our analysis highlights three main findings (Figure 2). 
---------------------------------------------- 
INSERT FIGURE 2 HERE 
---------------------------------------------- 
The ecosystem of an incubator is both a trigger and resource for collaborative 
sensemaking: The trend for converging technologies had been discussed in the wider 
innovation ecosystem for some time. This ecosystem, comprising of multiple stakeholders such 
as scientists, venture capitalists, consultants, universities and pharmaceutical companies, 
became both a trigger and a resource for collaborative sensemaking. The TMT’s discussions 
with stakeholders highlighted the need to investigate the implications of this particular trend 
for SBC’s incubation practice. The process of prospective sensemaking that followed drew on 
this ecosystem as a resource for collective meaning making. This process allowed the 
management team to create multiple interpretations of a particular phenomenon (in this case 
technology convergence) and, through these, to identify opportunities and potential 
organizational challenges.  
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Collective prospective sensemaking informs incubator strategy to maintain legitimacy 
within the ecosystem: Prospective sensemaking centred on the strategic implications for SBC, 
triggered by the potential for delivering unmet patient needs through the practical application 
of Convergence. In other words, SBC’s TMT was working ‘with’ the ecosystem to make sure 
that the incubator was working ‘for’ the ecosystem by continuing to be perceived as a legitimate 
incubator. In line with prior research, we use the notion of legitimacy in order to describe 
whether it is appropriate for an organizations to operate in a particular way in a specific domain 
(Suchman, 1995). Prospective sensemaking quickly affected the positioning of SBC. Members 
of the TMT used the phrase ‘convergence agenda’ to describe the future direction of the 
incubator. This positioning was also manifest in structural changes towards convergent medical 
technologies; for instance, through the recruitment of tenant firms but also the formation of 
new alliances. 
Collective prospective sensemaking may result in critical sensemaking outcomes 
(fragmentation of meaning and the anticipation of legitimacy challenges). We use the notion 
of ‘critical sensemaking outcomes’ to describe the emergence of differences in stakeholder 
interpretations that affect the positioning of the incubator. As SBC engaged in further 
prospective sensemaking by collaborating with stakeholders in the wider ecosystem, they saw 
that stakeholders’ understandings of Convergence did not align. In contrast, the term seemed 
to be adopted in ever widening circles, and its meaning became ever more fragmented. Over 
time fragmentation of meaning increased to the point where it became very opaque as to what 
the phenomenon actually was. This fragmentation of meaning and the fact that SBC used the 
phrase ‘convergence agenda’ to communicate its positioning resulted in the anticipation of a 
legitimacy challenge: How could SBC credibly portray its strategy to their ecosystem if they 
were unsure what Convergence actually was? The maintenance of legitimacy is crucial as 
science incubators and catalysts are often founded based on a particular agenda, which becomes 
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the mechanism to attract funding (Hsu et al., 2003; Phan et al., 2005). Their mission is hard-
wired into the tenants they recruit, their founding investors and shareholders, as well as the 
capabilities and processes through which incubation is actually delivered. Prospective 
sensemaking is thus a means to anticipate issues, such as legitimacy challenges in the wider 
ecosystem, prior to the need for significant structural realignment of the organisation. This is 
an important finding, as the very structure of science catalysts, which often involves public-
private partnerships, requires the delicate maintenance of legitimacy in order to secure financial 
and political support and to be regarded as a suitable host for fledgling innovations by leading 
scientists. 
Critical sensemaking outcomes result in repositioning of espoused strategy to maintain 
legitimacy: In the initial phase of our inquiry, SBC’s espoused strategy used the phrase 
‘Convergence Agenda’. This phrase was used in multiple meetings in which authors were 
present and it was also included in slide decks shown at presentations to stakeholders and 
investors. When legitimacy challenges were anticipated, SBC did not dismiss the relevance of 
technology convergence. Rather, anticipated legitimacy challenges resulted in a process of 
realignment of the ‘espoused’ incubator strategy and the underlying organizational capabilities, 
processes and networks that they developed and maintained. Prospective sensemaking also 
resulted in the anticipation of potential future capability shifts. This involved the questioning 
of SBC’s current business model, the composition of tenants, and other aspects. While these 
changes were considered inevitable, resolving the legitimacy challenge required abandoning 
the term ‘Convergence’ as a key communicating device of SBC’s espoused strategy. Adopting 
the term ‘Future Health’ as espoused strategy allowed the incubator to frame their activities to 
the market more credibly, while organizationally embracing the opportunities of the underlying 
trend of technology convergence. 
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5.2 Theoretical implications 
In this paper, we show the importance of prospective sensemaking as a means by which the 
management team of a science incubator engages with technological uncertainty. This provides 
new insight into the ways in which incubators anticipate technological and industry level 
change and offers the following theoretical contributions to the literature on science incubation: 
First, this paper contributes to extant research on the complex relationship between science 
incubators and the wider innovation ecosystem in which they operate. Indeed, incubators are 
often considered an important vehicle that connects entrepreneurs located within the incubator 
with other actors in the ecosystem (Hsu et al., 2003). Prior research has already started to 
describe more complex, synergistic interactions between incubators and other actors 
(Bøllingtoft & Ulhøi, 2005). This also involves the role of sensemaking as a way to explore 
changes in a particular technological field (Möller, 2010). This paper adds to this debate by 
highlighting the role of an incubator’s TMT, as a particular group of actors, through which 
such interactions unfold. In particular, we show that the TMT acts as an orchestrator of 
collective, prospective sensemaking and thus becomes a mediator between the stakeholders in 
the wider ecosystem and an incubator’s positioning and structure over time. Providing a more 
nuanced, micro-level perspective on the role of the TMT as they seek to address technological 
ambiguity, opens the black box of incubation management. It contributes to extant studies that 
focused on the ‘delivery’ of science incubation (Bergek & Norrman, 2008; Markovitch et al., 
2017), the relationship between the business environment and incubation models (e.g. Chandra 
& Chao, 2016; Hsu et al., 2003), and how ‘incubation’ as a particular form of economic activity 
has changed over time (Mian et al., 2016). 
Second, our findings reveal that responding to technological change is not only about 
adapting the structural conditions of an incubator. Rather, it is about changing the positioning 
such that the incubator maintains legitimacy in the wider ecosystem. These findings contribute 
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to prior research on science incubators that particularly addresses the stakeholder dynamics 
involved in these organizations (McAdam et al., 2016; Nicolopoulou et al., 2017; Sá & Lee, 
2012). Indeed, SBC was co-funded by a big-pharma company, a charity, and government, and 
thus needed to not only respond to the demands of these stakeholders, but also remain attuned 
to its positioning as an ‘incubator of choice’ for leading scientists. Incubators often combine 
the interests of private business with contributions to the public good (Nicolopoulou et al., 
2017; Sentana et al., 2017). The SBC case demonstrates two instances in which prospective 
sensemaking resulted in a legitimacy maintaining repositioning. Initially, SBC described its 
positon by using the phrase ‘convergence agenda’, this was later repositioned as ‘Future 
Health’. While the first positioning set in motion structural changes to the incubator (such as 
the formation of an alliance, seeking of new tenants, and decisions about resource allocations 
to deliver certain events and workshops), the second reposition maintained the strategic 
trajectory but (by repositioning) aimed to maintain the incubator’s legitimacy as the notion of 
convergence became problematic.  
Third, our findings suggest that collective prospective sensemaking may result in, what we 
call, critical sensemaking outcomes: the fragmentation (rather than alignment) of meaning 
regarding a particular trend and based on that the perceived challenge to the incubator’s 
legitimacy. While the involvement of stakeholders from the wider ecosystem of firms was 
intentional in order to explore ‘Convergence’ as a phenomenon, our analysis reveals that the 
fragmentation of meaning that emerged in phase 2 was also a result of the multiplicity of 
perspectives. Maitlis (2005) already highlights how such fragmentation might arise through 
multiple, individualistic accounts. However, while her study foregrounds the positive 
implication of fragmentation (the potential of new insights) the SBC case suggests that the 
fragmentation of meaning was an important trigger for the anticipation of legitimacy 
challenges. This is in line with Gephart et. al. (2010), who already highlight the relationship 
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between sensemaking and legitimacy. Thus, the SBC case demonstrates that prospective 
sensemaking is an important political activity that allows an organisation to anticipate 
responses to uncertainty-driven change before a course of action becomes embedded to such 
an extent, that organisational legitimacy and thus the future of the organization are placed in 
doubt. 
7. Conclusions  
As technologies advance the role of incubators as orchestrators of entrepreneurship and 
innovation becomes ever more challenging. Located at the intersection of academia, 
entrepreneurship, big-pharma and government, incubators must not only anticipate 
technological changes but also incorporate them into the very fabric of the incubator, if they 
wish to remain relevant and valuable members of their ecosystem. Yet, remaining relevant is a 
delicate balancing act of prospective sensemaking. It requires incubators to respond to 
anticipated change in collaboration with members from their ecosystem, without damaging 
their legitimacy within that very ecosystem of stakeholders.  
The findings presented in this paper are subject to limitations. While the longitudinal, 
single case design sheds light on the processes and outcomes of collaborative sensemaking 
over time, it does not allow us to make inferences about the conditions under which critical 
sensemaking outcomes are more or less likely. Therefore, we encourage future comparative 
studies to investigate the role of stakeholder diversity as well as other contextual characteristics 
for how incubators evolve (such as the speed of technological change).  
Our findings also have implications for the management of science incubators as well as 
policy. Managers of science incubators benefit from deep insights into the process and 
outcomes of SBC’s engagement with stakeholders in their particular ecosystem. We illustrates 
how collective, prospective sensemaking enables the identification of strategic options in the 
face of technological uncertainty, whilst ensuring legitimacy by embedding stakeholders into 
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the decision making process. Moreover, our findings are also of relevance for policy makers 
seeking to design governance regimes that support long-term incubator viability. While 
incubators are often established through a collaboration between multiple public and / or 
private organizations, our findings suggest that incubators should take an ecosystem view when 
constructing supervisory boards. This internalizes the prospective sensemaking dynamics 
described above, ensures continuous sensitivity to legitimacy challenges, and thus supports the 
evolution of the incubator in line with changing environments. 
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Table 1. Overview of data sources 
Data sources Data description Use for data analysis 
Interviews 
 
 Total of 34 interviews 
 26 interviews with SBC 
management (CEO, COO, 
Marketing Manager, Entrepreneur 
in Residence) 
 8 Interviews with directors of 
tenant companies 
 Background information on bioscience 
industry 
 Background information on SBC 
 Reflective accounts of technology 
convergence and implications for SBC  
Workshops  Documentation of convergence 
workshop in 2013 
 Full transcript of half day 
convergence workshop in October 
2015 
 Protocol of convergence workshop 
2015 
 Observation and documentation of 
Health Future event 2016 
 Insight into prospective sensemaking as 
it unfolded in the interaction of SBC staff 
and industry experts 
SBC Documentation  7 SBC Strategy and Planning 
Documents  
 Background information on SBC 
 Insight into SBC top management 
prospective sensemaking on technology 
convergence 
Industry reports   9 Industry reports on technology 
convergence in the biosciences 
 Insights into industry wide discussion on 
the definition of convergence and the 
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Table 2. Timeline of events 
Phase Key events Implications 
Phase 1:  
Convergence – making sense 
of an emerging trend (2013-
2014) 
 SBC organizes workshop as part 
of the annual Open Innovation 
Summit devoted to technology 
convergence: “Convergent 
Medical Technologies” 
 Invitation of multiple 
stakeholders and industry 
experts 
 Whitepaper on the strategic 
implications of technology 
convergence for science incubation 
at SBC 
 Alertness of SBC management to 
engage with the organizational 
changes necessary to leverage 
convergence 
 Convergence integrated in SBC 
strategy: ‘Convergence agenda’ 
Phase 2:  
Fragmentation of meaning 
and anticipated legitimacy 
challenge (2015) 
 The notion of technology 
convergence gains traction in the 
wider environment with major 
conferences devoted to the topic 
 SBC continues to make sense of 
the implications of convergence 
by inviting stakeholders to a 
workshop intended to further 
clarify the strategic implications 
for SBC  
 SBC starts to accept additional 
tenant firms that represent 
convergent technologies  
 Formation of alliance with Cell 
Therapy Catapult 
 Experts agree that convergence is an 
important phenomenon with major 
implications for health care 
 The boundaries of the phenomenon 
become increasingly blurred  
 Increasing concerns about ability to 
communicate ‘convergence’ to 
health sector in UK 
Phase 3:  
Repositioning: From 
convergence to ‘Future 
Health’ (2016) 
 The trend of convergent 
technologies is firmly 
established in scientific circles 
 The terminology of convergence 
seen as incompatible with health 
stakeholders in UK 
 Use of Open Innovation Summit 
to further commit to convergent 
technologies yet under the new 
positioning of ‘future health’ 
 Repositioning of ‘convergence 
agenda’ as ‘The Future of Health’. 
 Continued engagement with Cell 
Therapy Catapult alliance 
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Blurring / bridging of disciplinary 
boundaries 
How use convergence to deliver 
unmet patient need 
Collective 
Sensemaking  
Alertness about potential capability 
gaps 
Adoption in health sector 
Financing of convergent technologies 






Convergence interpreted from 
multiple perspectives 
Boundaries of phenomenon become 
extended and blurred 
Anticipated legitimacy 
challenge 
Need to justify incubator capability to 
stakeholders 







Reframing of terminology 
Publication and promotion of new 
framing 
Incubator structure 
Change in composition of tenant 
portfolio 
Adapting incubation model to 
incorporate orchestration of diverse 
players 
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First-order themes and  
supporting evidence 
Prospective sensemaking around convergence 
Sensemaking 
triggers 
Blurring / bridging of disciplinary boundaries 
“Explore “unmet need” in healthcare to identify potential opportunities for SBC and reinforce SBC’s role as a Catalyst for innovation” (SBC Meeting Minutes) 
“Stevenage Bioscience Catalyst will be defining convergent medical technologies as those bridging the gap between pharmaceuticals and medical 
technology, a mining of synergistic technologies.” (Workshop Minutes) 
Deliver unmet patient need 
“There are people outside pharma and biotech who are working on convergence - future events should include these communities as well” (Workshop Participant) 
“innovation in terms of devices or diagnostics or drugs or technology. For example, one of our tenants, […] is looking to apply what they’ve learnt about 





Alertness about potential capability gaps 
“Bring in expertise from outside healthcare to catalyse organisational change“ (SBC White paper) 
“Move away from the NHS as the (only) endpoint” (SBC Whitepaper) 
Adoption in health sector 
“Some middle management comfortable with technology innovation, but senior management only marginally engaged due to lack of ROI data” (SBC White Paper) 
“Working out how to divide incremental value between the various players” (SBC White Paper) 
“Few in healthcare understand customer experience and have a product view of life” (SBC White Paper) 
Financing of convergent technologies 
“People are starting to specialise in areas for investing meaning it may be difficult to find investors for CMT [Convergent Medical Technologies] as it covers 
multiple areas. In this case it may only make sense to the customer to invest.” (SBC Whitepaper) 
“Many investors follow ‘invest in what you know’, making CMT less appealing to them” (SBC Whitepaper) 
Critical sensemaking outcomes 
Fragmentation 
of meaning 
Convergence interpreted from multiple perspectives 
“So anyway that was one of my convergent strands, the second convergent strand before we diverge was around microelectronics. And I think that’s where the whole 
convergence of science between optics, electronics and physics to try to create… well particularly things that impact with neuroscience has massive opportunity 
where you could replace drug treatments with microelectronics in effect ultimately. I think that’s a different level again and that’s probably more one that the likes of 
GSK will be investing in for long term.” (Workshop participant) 
Boundaries of phenomenon become extended and blurred 
“There is a whole spectrum which runs from wellness through prevention and on to maintenance/monitoring of patients after disease diagnosis.” (Workshop 
participant) 
 “Just the last piece of this convergence issue is we’ve talked about the technologies, the patients but there’s this spectrum between wellness and health that is 
increasingly emerging as well, and diabetes is a particular one.” (Workshop participant) 











Need to justify incubator capability to stakeholders 
“It’s that kind of cross-industry thinking. […] GSK collaborates a lot with McLaren […] You think, “Why is GSK collaborating with McLaren? […]” GSK does a 
lot of manufacturing drugs […] and McLaren does manufacturing. […] So we’re always slightly having to prove ourselves […]” (Entrepreneur-in Residence) 
“here’s the question about the convergence and you were talking about this earlier. […] It’s a very awkward conversation about “I get paid by the patients and by 
outcomes and I can do these five tasks and I know I have a guaranteed revenue” (Workshop Participant) 
 “it’s about what do you do […] and then how do you do it so it’s not just okay we have tools but it’s also how do I deliver it and how do I ensure there’s patient 
traction in that process?” (Workshop Participant) 
Lack of ability to explain convergence to stakeholders 
Interviewer: Was there the worry that you do spread yourself too thinly?  
“It’s partly that. And also this philosophical, you are doing this so well why do you want to do this? Our business intelligence and our insight into the future of 
healthcare says we don’t do this none of this will be relevant in 5 to 10 years”. (CEO) 
Incubator strategy to maintain legitimacy 
Incubator (re-) 
positioning 
(Re-) framing of terminology 
“The definition is still the same whether it’s called convergence or ‘Future Health’. It’s about bringing IT, electronics and engineering together to solve the next 
generation of biological problems.” (CEO) 
Publication and promotion of framing 
“And the question and the debate for me is, would it be enough to use the same models that we have used so far, or do we have to put a new flavour or a new shade, 
and build on our model in order to really enhance the prospects for this industry ecosystem creation. And importantly, how do we make it Stevenage Plus. How do 
we show that we capitalize on innovation in the Cell and Gene Therapy space across the UK” (CEO) 
Incubator 
structure 
Change in tenant portfolio 
“Diversity was emphasised as being needed on the SBC CMT campus - in terms of the kinds of companies attracted, both 'cornerstone' and smaller tenants. the kinds 
of people involved etc. - to cover such a broad and rapidly / chaotically evolving space and place bets in many areas, e.g. in devices field, in genomics area etc. 
(Workshop protocol) 
“But then what we’ll do is have focus, we’ve got this antibody company in little cluster so what we can do with them? We’ve got a start-up community of regen-med 
companies with GE, GSK and Cell Therapy Catapult coming so there’s got to be something to do there with that cluster. So what else can we do, who do we need in 
the picture and we’re ready to go. That’s a whole supply chain that you can look at”. (CEO) 
Change in incubation model 
“It’s how you look for us going forward, what skills are needed and particularly because we’re going into campus, science park whatever you want to call it […] 
Because as we grow we’re not going to be able to say bring in two, three more buildings on board in the next three years that are going to have an extra ten, 15 
staff. It just isn’t going to happen, we’ll have two or three maybe.” (COO) 
“So actually if you get your head round this very, very few of those companies are actually covering all of these areas and what we were trying to tell Martino was 
basically the role of the SBC is to sink itself in the middle and say come and join us because we’re going to be… we can join up the dots.” (Workshop participant) 
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Figure 2: Prospective sensemaking in situations of technological change in science incubation 
 
 
 
 
 
 
 
